Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO6874281 (Simlukafusp Alfa) + Pembrolizumab in Advanced Melanoma
NCT03875079Phase 1Completed
- Sponsor
- Roche
- Start
- Jun 2019
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 7
01
Overview
Phase 1, randomised, open-label trial of simlukafusp alfa in melanoma (3 arms), sponsored by Roche. Primary endpoint: Percentage of participants with adverse events at 24 months. Started Jun 2019; status: completed.
02
Drugs
simlukafusp alfa
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03875079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03875079.